Dysregulation of the NLRP3 inflammasome complex and related cytokines in patients with multiple myeloma

References

• Manier S, Sacco A, Leleu X, Ghobrial IM, Roccaro AM. Bone marrow microenvironment in multiple myeloma progression. J Biomed Biotechnol. 2012;2012:157496. doi: 10.1155/2012/157496
   PubMed Web of Science ®Google Scholar
• Mahindra A, Hideshima T, Anderson KC. Multiple myeloma: biology of the disease. Blood Rev. 2010;24(Suppl 1):S5–11. doi: 10.1016/S0268-960X(10)70003-5
   PubMedGoogle Scholar
• Tsirakis G, Pappa CA, Kaparou M, Boula A, Katsomitrou A, Kyriakaki S, et al. The relationship between soluble receptor of interleukin-6 with angiogenic cytokines and proliferation markers in multiple myeloma. Tumour Biol. 2013;34:859–64. doi: 10.1007/s13277-012-0618-6
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011;117:3720–32. doi: 10.1182/blood-2010-07-273417
   PubMed Web of Science ®Google Scholar
• Vangsted AJ, Klausen TW, Abildgaard N, Andersen NF, Gimsing P, Greqersen H, et al. Single nucleotide polymorphisms in the promoter region of the IL1B gene influence outcome in multiple myeloma patients treated with high-dose chemotherapy independently of relapse treatment with thalidomide and bortezomib. Ann Hematol. 2011;90:1173–81. doi: 10.1007/s00277-011-1194-3
   PubMed Web of Science ®Google Scholar
• Vangsted AJ, Nielsen KR, Klausen TW, Haukaas E, Tiønneland A, Voqel U. A functional polymorphism in the promoter region of the IL1B gene is associated with risk of multiple myeloma. Br J Haematol. 2012;158:515–8. doi: 10.1111/j.1365-2141.2012.09141.x
   PubMed Web of Science ®Google Scholar
• Tschopp J, Martinon F, Burns K. NALPs: a novel protein family involved in inflammation. Nat Rev Mol Cell Biol. 2003;4:95–104. doi: 10.1038/nrm1019
   PubMed Web of Science ®Google Scholar
• Tschopp J, Schroder K. NLRP3 Inflammasome activation: the convergence of multiple signalling pathways on ROS production? Nat Rev Immunol. 2010;10:210–5. doi: 10.1038/nri2725
   PubMed Web of Science ®Google Scholar
• Sutterwala FS, Ogura Y, Szczepanik M, Lara-Tejero M, Lichtenberqer GS, Grant EP, et al. Critical role for NALP3/CIAS1/cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity 2006;24:317–27. doi: 10.1016/j.immuni.2006.02.004
   PubMed Web of Science ®Google Scholar
• Ichinohe T, Lee HK, Ogura Y, Flavell R, Iwasaki A. Inflammasome recognition of influenza virus is essential for adaptive immune responses. J Exp Med. 2009;206:79–87. doi: 10.1084/jem.20081667
   PubMed Web of Science ®Google Scholar
• Okamoto M, Liu W, Luo Y, Tanaka A, Cai X, Norris DA, et al. Constitutively active inflammasome in human melanoma cells mediating autoinflammation via caspase-1 processing and secretion of interleukin-1beta. J Biol Chem. 2010;285:6477–88. doi: 10.1074/jbc.M109.064907
   PubMed Web of Science ®Google Scholar
• Wei Q, Mu K, Li T, Zhang Y, Yang Z, Jia X, et al. Deregulation of the NLRP3 inflammasome in hepatic parenchymal cells during liver cancer progression. Lab Invest. 2014;94:52–62. doi: 10.1038/labinvest.2013.126
   PubMed Web of Science ®Google Scholar
• Allen IC, Tekippe EM, Woodford RM, Uronis JM, Holl EK, Roqers AB, et al. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J Exp Med. 2010;207:1045–56. doi: 10.1084/jem.20100050
   PubMed Web of Science ®Google Scholar
• Grogan TM, van Camp B, Kyle RA. Plasma cell neoplasms. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds.) Pathology and genetics of tumours of haematopoietic and lymphoid tissues (World Health Organization Classification of Tumours). Lyon: IARC Press; 2001. p .142–5.
   Google Scholar
• Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412–20. doi: 10.1200/JCO.2005.04.242
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C(T)). Methods. 2001;25:402–8. doi: 10.1006/meth.2001.1262
   PubMed Web of Science ®Google Scholar
• Durie BG, Harousseau JL, Miguel JS, Bladé J, Barloqie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467–73. doi: 10.1038/sj.leu.2404284
   PubMed Web of Science ®Google Scholar
• Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med. 2009;15:1170–8. doi: 10.1038/nm.2028
   PubMed Web of Science ®Google Scholar
• Gris D, Ye Z, Iocca HA, Wen H, Craven RR, Gris P, et al. NLRP3 plays a critical role in the development of experimental autoimmune encephalomyelitis by mediating Th1 and Th17 responses. J Immunol. 2010;185:974–81. doi: 10.4049/jimmunol.0904145
   PubMed Web of Science ®Google Scholar
• Shaw PJ, Lukens JR, Burns S, Chi H, McGarqill MA, Kanneqanti TD. Cutting edge: critical role for PYCARD/ASC in the development of experimental autoimmune encephalomyelitis. J Immunol. 2010;184:4610–4. doi: 10.4049/jimmunol.1000217
   PubMed Web of Science ®Google Scholar
• Kumar H, Kumagai Y, Tsuchida T, Koeniq PA, Satoh T, Guo Z, et al. Involvement of the NLRP3 inflammasome in innate and humoral adaptive immune responses to fungal beta-glucan. J Immunol. 2009;183:8061–7. doi: 10.4049/jimmunol.0902477
   PubMed Web of Science ®Google Scholar
• Chung Y, Chang SH, Martinez GJ, Yang XO, Nurieva R, Kang HS, et al. Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity 2009;30:576–87. doi: 10.1016/j.immuni.2009.02.007
   PubMed Web of Science ®Google Scholar
• Robinson D, Shibuya K, Mui A, Zonin F, Murphy E, Sana T, et al. IGIF Does not drive Th1 development but synergizes with IL-12 for interferon-gamma production and activates IRAK and NFkappaB. Immunity 1997;7:571–81. doi: 10.1016/S1074-7613(00)80378-7
   PubMed Web of Science ®Google Scholar
• Chen GY, Liu M, Wang F, Bertin J, Núñez G. A functional role for Nlrp6 in intestinal inflammation and tumorigenesis. J Immunol. 2011;186:7187–94. doi: 10.4049/jimmunol.1100412
   PubMed Web of Science ®Google Scholar
• Vladimer GI, Marty-Roix R, Ghosh S, Weng D, Lien E. Inflammasomes and host defenses against bacterial infections. Curr Opin Microbiol. 2013;16:23–31. doi: 10.1016/j.mib.2012.11.008
   PubMed Web of Science ®Google Scholar
• Arend WP, Palmer G, Gabay C. IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev. 2008;223:20–38. doi: 10.1111/j.1600-065X.2008.00624.x
   PubMed Web of Science ®Google Scholar
• Turesson I, Abildgaard N, Ahlgren T, Dahl I, Holmberg E, Hjorth M, et al. Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factors. Br J Haematol. 1999;106:1005–12. doi: 10.1046/j.1365-2141.1999.01651.x
   PubMed Web of Science ®Google Scholar
• Bauernfeind FG, Horvath G, Stutz A, Alnemri ES, MacDonald K, Speert D, et al. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol. 2009;183:787–91. doi: 10.4049/jimmunol.0901363
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Dhodapkar KM, Palucka AK. Interactions of tumor cells with dendritic cells: balancing immunity and tolerance. Cell Death Differ. 2008;15:39–50. doi: 10.1038/sj.cdd.4402247
   PubMed Web of Science ®Google Scholar
• Tucci M, Stucci S, Strippoli S, Dammacco F, Silvestris F. Dendritic cells and malignant plasma cells: an alliance in multiple myeloma tumor progression? Oncologist 2011;16:1040–8. doi: 10.1634/theoncologist.2010-0327
   PubMed Web of Science ®Google Scholar
• Ni H, Erqin M, Huang Q, Qin JZ, Amin HM, Martinez RL, et al. Analysis of expression of nuclear factor kappa B (NF-kappa B) in multiple myeloma: downregulation of NF-kappa B induces apoptosis. Br J Haematol. 2011;115:279–86. doi: 10.1046/j.1365-2141.2001.03102.x
   Web of Science ®Google Scholar
• Houde C, Li Y, Song L, Barton K, Zhang Q, Godwin J, et al. Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines. Blood 2004;104:3697–704. doi: 10.1182/blood-2003-12-4114
   PubMed Web of Science ®Google Scholar
• Derksen PW, Tjin E, Meijer HP, Klok MD, Macgillavry HD, van Oers MH, et al. Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc Natl Acad Sci U S A. 2004;101:6122–7. doi: 10.1073/pnas.0305855101
   PubMed Web of Science ®Google Scholar
• Eisenbarth SC, Flavell RA. Innate instruction of adaptive immunity revisited: the inflammasome. EMBO Mol Med. 2009;1:92–8. doi: 10.1002/emmm.200900014
   PubMed Web of Science ®Google Scholar
• Heider U, Langelotz C, Jakob C, Zavrski I, Fleissner C, Eucker J, et al. Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. Clin Cancer Res. 2003;9:1436–40.
   PubMed Web of Science ®Google Scholar
• Seidel C, Hjertner Ø, Abildgaard N, Heickendorff L, Hjorth M, Westin J, et al. Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood 2001;98:2269–71. doi: 10.1182/blood.V98.7.2269
   PubMed Web of Science ®Google Scholar
• Hata H. Bone lesions and macrophage inflammatory protein-1 alpha (MIP-1a) in human multiple myeloma. Leuk Lymphoma. 2005;46:967–72. doi: 10.1080/10428190500066636
   PubMed Web of Science ®Google Scholar
• Terpos E, Szydlo R, Apperley JF, Hatjiharissi E, Politou M, Meletis J, et al. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 2003;102:1064–9. doi: 10.1182/blood-2003-02-0380
   PubMed Web of Science ®Google Scholar